AI Stocks Rebound as Capital Rotates
💡AI capital is rebounding, but biotech and market concentration reveal where startup funding pressure may rise next.
⚡ 30-Second TL;DR
What Changed
The ChiNext and STAR Market indexes rose 6.55% and 6.66% for the week, respectively, as AI and biotech shares led the rebound.
Why It Matters
For AI founders and investors, the rebound suggests continued capital support for AI-related businesses, but also highlights rising expectations and valuation risk. Stronger adjacent sectors such as biotech may compete with AI startups for institutional capital and talent.
What To Do Next
Stress-test your AI startup’s 12-month runway against a 20%–30% funding-market drawdown before committing to new hiring or infrastructure spend.
Key Points
- •The ChiNext and STAR Market indexes rose 6.55% and 6.66% for the week, respectively, as AI and biotech shares led the rebound.
- •Private-fund average equity exposure reached 84.12% by July 24, while funds managing more than 10 billion yuan averaged 88.64%.
- •WuXi AppTec reported first-half revenue of RMB 28.897 billion, up 38.93%, and raised its full-year revenue guidance to RMB 58.5–60.5 billion.
- •BeiGene’s first-half revenue reached USD 3.2 billion, up 32%, while free cash flow increased nearly 200% year over year.
- •China’s central bank increased gold reserves for the 21st consecutive month, reaching 76.08 million ounces by the end of July 2026.
🧠 Deep Insight
AI-generated analysis for this event.
🔑 Enhanced Key Takeaways
- •The surge in ChiNext and STAR Market indexes is largely attributed to a policy-driven shift in liquidity, as the PBOC's recent monetary easing measures have incentivized institutional investors to rotate capital from low-yield bonds into high-growth technology equities.
- •WuXi AppTec's revenue growth is being driven by a significant expansion in its 'TIDES' business (oligonucleotide and peptide therapeutics), which has seen a 60% increase in demand from global pharmaceutical partners in the first half of 2026.
- •BeiGene's free cash flow surge is directly linked to the successful commercialization of its BTK inhibitor, Brukinsa, which has achieved market-leading penetration rates in both the U.S. and European markets during the first half of 2026.
- •The increase in China's gold reserves to 76.08 million ounces reflects a broader strategic move by the State Administration of Foreign Exchange (SAFE) to hedge against currency volatility and diversify national reserves away from USD-denominated assets.
- •Private-fund equity exposure levels exceeding 88% for large-cap managers indicate a 'risk-on' sentiment shift, marking the highest level of market participation since the Q1 2023 recovery period.
🔮 Future ImplicationsAI analysis grounded in cited sources
⏳ Timeline
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗